Isomorphic Labs on Tuesday closed a $2.1 billion funding round led by Thrive Capital, marking the second-largest biotech fundraise in history as AI healthcare investments surge across drug discovery, hospital operations, and clinical diagnostics. According to Endpoints News, only Altos Labs has raised more capital in the biotech sector.
The Alphabet-founded company, led by Nobel Prize winner Demis Hassabis, develops AI models for drug discovery including AlphaFold 3, which predicts protein structures and interactions with small molecules, peptides, and antibodies. Isomorphic President Max Jaderberg told Forbes the funding represents “a lot of validation of what we’ve been building out the past four-and-a-half, almost five, years.”
Meanwhile, hospitals are deploying AI agents for medical transcription, electronic health records management, and patient history analysis, but enterprise identity management systems struggle to govern these non-human identities at scale.
Hospital AI Agents Create Identity Management Crisis
AI agents are now running medical transcription, updating electronic health records, and surfacing patient histories in real-time hospital environments, but 85% of enterprises remain stuck in pilot phases due to identity governance gaps. Cisco President Jeetu Patel told VentureBeat at RSAC 2026 that only 5% of companies have moved AI agents into production, creating an 80-point trust gap.
The core issue centers on accountability and access control. CISOs cannot inventory, scope, or revoke machine identities at the speed AI agents operate, leaving hospitals vulnerable to unauthorized system access. IANS Research found that most businesses lack mature role-based access controls for human identities, and AI agents significantly complicate this challenge.
IBM’s 2026 X-Force Threat Intelligence Index reported a 44% increase in attacks exploiting public-facing applications, driven by missing authentication controls and AI-enabled vulnerability discovery. For hospitals processing sensitive patient data, these security gaps pose regulatory and operational risks that prevent widespread AI agent deployment.
Administrative Bottlenecks Drive Healthcare AI Investment
Venture capitalists are targeting healthcare’s administrative inefficiencies, where fax machines and manual processes create massive patient care gaps between primary care referrals and specialist appointments. Phoenix-based Basata, founded by former Lyft executive Kaled Alhanafi and ex-Medtronic engineer Chetan Patel, automates referral processing to address intake backlogs.
According to TechCrunch, specialty practices receive hundreds or thousands of fax-based referrals with small administrative teams, causing patients to fall through cracks not due to capacity constraints but processing delays. Alhanafi described his father’s cardiology referral experience: only one of three practices called back within weeks, another responded after surgery completion, and the third never responded.
The administrative burden extends beyond referrals. Medical practices spend significant resources on prior authorization requests, insurance verification, and appointment scheduling—all areas where AI automation can reduce costs and improve patient access to care.
Drug Discovery AI Attracts Record Funding
Isomorphic Labs’ $2.1 billion raise follows a $600 million funding round in 2025, demonstrating sustained investor confidence in AI-powered drug development. The company built its Isomorphic Labs Drug Design Engine (IsoDDE) on AlphaFold technology, which CEO Demis Hassabis used to win the 2024 Nobel Prize in Chemistry.
Jaderberg described IsoDDE as “like half a dozen AlphaFold breakthroughs” combined into a comprehensive drug design platform. The system works with proteins, small molecules, peptides, and antibodies to accelerate the traditionally costly and lengthy pharmaceutical development process.
Parallel investments target other healthcare AI applications. The Bill & Melinda Gates Foundation funded Kanvas Biosciences to develop synthetic bacterial microbiomes for treating environmental enteric dysfunction (EED), which affects 150 million children worldwide. Kanvas CEO Matthew Cheng told Forbes his company can pack 145 different bacterial strains into a single pill, compared to fewer than dozen strains in competing microbiome treatments.
Regulatory and Policy Challenges Emerge
The Trump administration is considering auto-enrolling newly eligible Medicare beneficiaries into Medicare Advantage plans or Accountable Care Organizations, potentially affecting how AI healthcare tools reach patients. CMS Director Chris Klomp told STAT News this approach would improve upon current fee-for-service defaults.
However, the Medicare Payment Advisory Commission found that Medicare paid $76 billion more for Medicare Advantage patients in 2025 than equivalent original Medicare coverage would have cost. This cost differential could impact funding available for AI healthcare initiatives and technology adoption in Medicare-serving providers.
The policy shift toward managed care models may accelerate AI adoption as Medicare Advantage plans seek operational efficiencies, but it could also create access restrictions through prior authorization requirements and narrow provider networks that limit where patients can receive AI-enhanced care.
What This Means
The healthcare AI sector is experiencing unprecedented investment momentum, but deployment faces structural challenges around identity management, regulatory frameworks, and administrative integration. Isomorphic Labs’ $2.1 billion raise signals confidence in AI drug discovery, while hospital AI agents remain constrained by security governance gaps that prevent production scaling.
The administrative automation opportunity appears most immediate, with clear ROI potential in referral processing, prior authorization, and appointment scheduling. However, the 80-point gap between pilot and production deployments suggests that identity management solutions must mature before hospitals can safely deploy AI agents at scale.
Policy changes around Medicare enrollment could accelerate or constrain AI adoption depending on implementation. Medicare Advantage plans’ cost pressures may drive AI efficiency investments, but access restrictions could limit patient exposure to AI-enhanced care delivery.
FAQ
What makes Isomorphic Labs’ funding round significant?
The $2.1 billion raise represents the second-largest biotech fundraise in history and demonstrates unprecedented investor confidence in AI drug discovery. The funding follows Isomorphic’s development of AlphaFold 3 and IsoDDE, which can design drugs using proteins, small molecules, and antibodies.
Why are hospital AI agents stuck in pilot phases?
Enterprise identity management systems cannot govern AI agents’ non-human identities at machine speed, creating accountability and security gaps. CISOs cannot inventory, scope, or revoke agent access to sensitive patient data systems, preventing production deployments despite successful pilots.
How could Medicare policy changes affect healthcare AI adoption?
Auto-enrollment in Medicare Advantage plans could accelerate AI adoption as insurers seek operational efficiencies, but may also create access restrictions through prior authorization and narrow networks. The $76 billion cost premium Medicare pays for Advantage plans could impact funding available for AI healthcare technology investments.
